X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, WuXi ATU will serve as a cell processing manufacturing partner for the planned global clinical development of CABA-201, a 4-1BB-containing fully human CD19-CAR T, in systemic lupus erythematosus and idiopathic inflammatory myopathies, or myositis.
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cabaletta Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 22, 2023
Details:
Through the partnership, Interius will leverage WuXi ATU's CTDMO platform for Good Manufacturing Process (GMP) manufacturing of Phase I clinical product and will advance INT-2104 in vivo CART program for B cell malignancies to the clinic.
Lead Product(s): INT-2104
Therapeutic Area: Oncology Product Name: INT-2104
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Interius BioTherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 08, 2023
Details:
Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems.
Lead Product(s): Aav Vectors
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
